Ian W. Rodger

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 460 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 399 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

Denis Riendeau, M. David Percival, S. Boyce et al. · British Journal of Pharmacology · 1997 · 326 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Induction of Cyclooxygenase-2 and Activation of Nuclear Factor-κB in Myocardium of Patients With Congestive Heart Failure

Samuel C. Y. Wong, Mitsumasa Fukuchi, Peter Melnyk et al. · Circulation · 1998 · 322 citations · Full text

Medicine, Cardiology, Cell Biology +15